Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer

• Status: Terminated
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: James Graham Brown Cancer Center; University of Louisville
• Collaborators: James Graham Brown Cancer Center; Novartis Pharmaceuticals; University of Louisville
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria:

• invasive lung cancer (small cell or non-small cell lung cancer)

• osteolytic bone metastasis determined by clinical exam, bone scan/XR

• age > 18 years

Exclusion Criteria:

• concurrent malignancy with a second primary

• renal failure (serum creatinine > 3mg/dl)

• pregnancy

• active rheumatoid arthritis

• intolerance to zoledronic acid